What is Beta Drugs Ltd (BETA) share price return in the past 10 years?

Data is not available for this company

What is the share price of Beta Drugs Ltd (BETA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Beta Drugs Ltd (BETA) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Beta Drugs?

The latest standalone P/E ratio of Beta Drugs as of 01-Jan-1970 is 163.32.

What is the P/B ratio of Beta Drugs Ltd (BETA)?

The latest standalone P/B ratio of Beta Drugs Ltd (BETA) as of 01-Jan-1970 is 14.96.

What is the 52-week high and low of Beta Drugs Ltd (BETA)?

The 52-week high of Beta Drugs Ltd (BETA) is Rs. 0.00 and the 52-week low is Rs. 0.00.

Beta Drugs Ltd (BETA)

Name: Beta Drugs Ltd (BETA)
Brand: Beta Drugs

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

BSE Share Price
Not Listed

Beta Drugs Ltd (BETA)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: BETA Pharmaceuticals & Drugs | Small Cap | Beta Drugs Share Price

BSE Share Price
Not Listed

Key Metrics

Valuation Multiples

Market Cap

₹2,341 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

₹37.3

TTM Sales

₹385 Cr.

Book Value per Share

₹235.8

P/E Ratio

56.43

Lower than its 5-year historical median

Industry PE

54.8

Price to Book (P/B)

8.93

Lower than its 5-year historical median

Price to Sales (P/S)

6.08

Lower than its 5-year historical median

EV/EBITDA

27.22

Lower than its 5-year historical median

Dividend Yield

NAN%

Profitability Efficiency

Return on Equity (ROE)

23.95%

Outperforms industry median

Return on Capital Employed (ROCE)

25.23%

Outperforms industry median

Return on Assets (ROA)

11.99%

Operating Profit Margin

20.6%

Net Profit Margin

11.71%

Gross Profit Margin

20.4%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Slowing versus 3-year growth rate

11.43%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

24.35%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

16.41%

Asset Quality

Promoter Holding

59.10%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹251 Cr.

Equity

₹11.1 Cr.

Face Value

₹10

All Time Low / High

₹0.00 / 0.00

Beta Drugs stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Weak

Check Price chart

Q.1 Is Beta Drugs Ltd a good quality company?

Beta Drugs Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Beta Drugs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Beta Drugs Ltd vs industry peers?

Beta Drugs Ltd revenue CAGR is 31.89%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Beta Drugs Ltd?

Promoters hold 59.10% of the Beta Drugs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Beta Drugs Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 39.39% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	21.9%	48.9%	28.6%	18.4%	16.9%	15.9%	26.9%	27.9%	27.3%	13.5%	-
Value Creation Index ⓘ	0.6	2.5	1.1	0.3	0.2	0.1	0.9	1.0	1.0	0.0	-
Growth Parameters ⓘ
Sales ⓘ	26.4	41.7	50.6	58.1	65.3	79.5	125	158	198	220	225
Sales YoY Gr.	-	57.9%	21.4%	14.8%	12.5%	21.7%	57.1%	26.5%	25.2%	11.4%	-
Adj EPS ⓘ	1.8	7.4	8.1	8.8	7	6.9	14.1	18.6	21.7	18.5	12.9
YoY Gr.	-	308.8%	9.3%	8.5%	-20.2%	-1.3%	104.1%	32%	16.6%	-15.1%	-
BVPS (₹) ⓘ	3.5	9.7	36.2	44.7	55.9	62.8	76.7	95.4	114.9	127.8	140.7
Adj Net Profit ⓘ	1.1	4.6	7.4	8	7.1	7	14.3	18.8	21.9	18.6	14
Cash Flow from Ops. ⓘ	-0.4	4.7	17.1	7.7	6.1	11.6	18.8	10.2	21.2	18	-
Debt/CF from Ops. ⓘ	-22.5	1.7	0.5	1	1.5	0.5	0.4	0.6	0.3	7.1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.6%	27.5%	20.8%	11.4%
Adj EPS ⓘ	29.4%	21.4%	9.4%	-15.1%
BVPSⓘ	49.1%	18%	18.5%	11.2%
Share Price	-	39.4%	27.1%	15.5%

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	69.4	112	37.7	21.7	14.6	11.7	20.2	21.7	20.7	15.2	9.6
Op. Profit Mgn % ⓘ	11.4	18.7	20.4	18.4	18	19.3	20.2	19.8	17	14.3	15
Net Profit Mgn % ⓘ	4.3	11.1	14.5	13.7	10.8	8.8	11.4	11.9	11.1	8.5	6.4
Debt to Equity ⓘ	3.8	1.4	0.2	0.2	0.2	0.1	0.1	0.1	0.1	1	-
Working Cap Days ⓘ	65	99	138	180	211	196	149	157	170	187	90
Cash Conv. Cycle ⓘ	2	26	47	63	73	66	41	49	51	46	68

Valuation of Beta Drugs - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Financials

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	51	66	91	116	184	227	296	362
Operating Expenses ⓘ +	41	54	73	91	141	174	236	288
Manufacturing Costs	6	8	10	13	17	24	32	41
Material Costs	27	33	44	59	94	106	149	171
Employee Cost	1	4	7	8	12	17	20	27
Other Costs ⓘ	6	9	12	12	17	27	34	49
Operating Profit ⓘ	9	12	18	25	43	53	60	75
Operating Profit Margin (%)	18.7%	17.9%	19.7%	21.3%	23.2%	23.4%	20.3%	20.6%
Other Income ⓘ +	0	0	0	1	1	1	1	6
Exceptional Items ⓘ	0	0	0	0	0	0	0	-5
Interest ⓘ	1	1	3	2	2	2	3	7
Depreciation ⓘ	2	3	4	7	7	10	10	13
Profit Before Tax ⓘ	7	8	12	16	34	41	49	57
Tax ⓘ	0	-0	3	4	9	10	12	15
Profit After Tax	7	8	9	12	25	31	36	42
PAT Margin (%)	13.4%	12.2%	10.4%	10.1%	13.5%	13.5%	12.3%	11.7%
Adjusted EPS (₹)	7.5	8.9	9.3	11.6	24.6	30.4	36.1	42.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	33	41	57	69	92	123	157	197
Share Capital ⓘ	9	9	10	10	10	10	10	10
Reserves ⓘ	24	32	47	59	83	113	148	187
Debt +	6	18	20	15	17	16	11	133
Long Term Debt	3	7	10	11	12	7	6	127
Short Term Debt	4	11	10	4	5	9	5	6
Minority Interest	0	0	0	0	0	0	0	0
Trade Payables	6	13	14	20	32	40	59	71
Others Liabilities ⓘ	4	12	17	16	22	25	35	44
Total Liabilities ⓘ	50	83	108	120	163	204	262	445
Fixed Assets
Net Fixed Assets ⓘ +	13	18	44	40	55	63	65	89
Gross Block	18	25	58	61	82	99	109	146
Accumulated Depreciation	5	8	14	21	27	37	45	57
CWIP ⓘ	1	15	0	3	0	0	0	0
Investments ⓘ	0	0	0	1	1	1	0	0
Inventories	3	10	12	16	22	31	50	60
Trade Receivables	14	25	32	34	45	63	79	103
Cash Equivalents ⓘ	12	3	5	10	17	19	29	147
Others Assets ⓘ	6	13	14	16	22	28	40	47
Total Assets ⓘ	50	83	108	120	163	204	262	445

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	17	0	8	19	30	23	31	36
PBT ⓘ	7	8	12	16	34	41	49	62
Adjustment ⓘ	15	2	2	7	5	2	-4	-6
Changes in Working Capital ⓘ	-5	-9	-6	-4	-10	-20	-14	-19
Tax Paid ⓘ	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-11	-21	-15	-6	-22	-19	-14	-36
Capex	-8	-21	-15	-6	-19	-18	-12	-37
Net Investments	0	-0	0	-0	0	0	1	0
Others ⓘ	-3	0	0	0	-2	-1	-3	1
Cash Flow From Financing Activity ⓘ +	5	12	9	-8	-1	-2	-7	118
Net Proceeds from Shares ⓘ	8	0	9	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-1	6	4	1	1	-4	-1	124
Interest Paid ⓘ	-1	-1	-3	-2	-2	-2	-3	-7
Dividend Paid ⓘ	0	0	0	0	0	0	0	0
Others ⓘ	-0	7	-1	-6	0	4	-4	1
Net Cash Flow ⓘ	12	-9	2	5	7	2	9	118

PARTICULARS	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	20.57	21.79	19.21	18.65	30.85	28.55	26.03	23.95
ROCE (%)	19.36	18.41	20.71	22.17	36.38	33.94	32.74	25.23
Asset Turnover Ratio	1.02	0.99	0.95	1.02	1.3	1.24	1.27	1.02
PAT to CFO Conversion(x)	2.43	0	0.89	1.58	1.2	0.74	0.86	0.86
Working Capital Days
Receivable Days	104.30	109.30	114.50	103.40	78.50	86.70	87.60	91.60
Inventory Days	20.20	34.10	44	44.60	38.20	42.70	49.60	55.20
Payable Days	82	105	113.60	108.60	101.30	124.70	121.60	139

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Beta Drugs Ltd FAQs

The current trading price of Beta Drugs on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Beta Drugs stood at ₹2,341 Cr

The latest P/E ratio of Beta Drugs as of 31-Dec-1969 is 163.3.

The latest P/B ratio of Beta Drugs as of 31-Dec-1969 is 14.96.

The 52-week high of Beta Drugs is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is ₹225 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company.

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Beta Drugs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Beta Drugs Ltd

No data to display

You have 44 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Beta Drugs Ltd (BETA)

Beta Drugs Ltd (BETA)

Beta Drugs stock performance